Regulatory scientific advice in drug development: does company size make a difference?

por Putzeist, Michelle, Mantel-Teeuwisse, Aukje K., Gispen-De Wied, Christine C., Hoes, Arno W., Leufkens, Hubert G.
Publicado 2010

Drug development for exceptionally rare metabolic diseases: challenging but not impossible

por Putzeist, Michelle, Mantel-Teeuwisse, Aukje K, Wied, Christine C Gispen-de, Hoes, Arno W, Leufkens, Hubert GM, de Vrueh, Remco LA
Publicado 2013

Regulatory Scientific Advice on Non-Inferiority Drug Trials

por Wangge, Grace, Putzeist, Michelle, Knol, Mirjam J., Klungel, Olaf H., Gispen-De Wied, Christine C., de Boer, Antonius, Hoes, Arno W., Leufkens, Hubert G., Mantel-Teeuwisse, Aukje K.
Publicado 2013